Daxor to Present at H.C. Wainwright 22nd Annual Global Investment Conference
September 10 2020 - 8:30AM
Daxor Corporation (NYSE MKT: DXR), an investment company with
innovative medical instrumentation and biotechnology operations
focused on blood volume measurement, today announces that Michael
Feldschuh, Daxor’s President & Chief Executive Officer, will
present at the virtual H.C. Wainwright 22nd Annual Global
Investment Conference on Tuesday, September 15, 2020, at 2:00 PM
ET.
The Company will present virtually and provide
updates about recent developments and key highlights including
progress with BVA-100 as well as be available to participate in
one-on-one meetings.
Event: H.C. Wainwright 22nd Annual Global
Investment Conference
Date: Tuesday, September 15th, 2020
Presentation: 2:00 PM ET - 2:20 PM ET
Register here:
https://www.meetmax.com/sched/event_61861/investor_reg_new.html?attendee_role_id=INVESTOR
HC Wainwright will take place on September 14th
through the 16th.
About Daxor Corporation
Daxor Corporation (NYSE: DXR) is an innovative
medical instrumentation and biotechnology company focused on blood
volume measurement. We developed and market the BVA-100® (Blood
Volume Analyzer), the first diagnostic blood test cleared by the
FDA to provide safe, accurate, objective quantification of blood
volume status and composition compared to patient-specific norms.
The BVA technology has the potential to improve hospital
performance metrics in a broad range of surgical and medical
conditions, including heart failure and critical care, by informing
treatment strategies, resulting in significantly improved patient
outcomes. Our mission is to partner with clinicians to incorporate
BVA technology into standard clinical practice and improve the
quality of life for patients. For more information, please visit
our website at Daxor.com.
Forward-Looking Statements
Certain statements in this release may include
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995, including without
limitation, statements regarding the impact of hiring sales staff
and expansion of our distribution channels. Forward-looking
statements are predictions, projections and other statements about
future events that are based on current expectations and
assumptions and, as a result, are subject to risks and
uncertainties. Many factors could cause actual future events to
differ materially from the forward-looking statements in this
release, including, without limitation, those risks associated with
our post-market clinical data collection activities, benefits of
our products to patients, our expectations with respect to product
development and commercialization efforts, our ability to increase
market and physician acceptance of our products, potentially
competitive product offerings, intellectual property protection,
FDA regulatory actions, our ability to integrate acquired
businesses, our expectations regarding anticipated synergies with
and benefits from acquired businesses, and additional other risks
and uncertainties described in our filings with the SEC.
Forward-looking statements speak only as of the date when made.
Daxor does not assume any obligation to publicly update or revise
any forward-looking statements, whether as a result of new
information, future events or otherwise.
Investor Relations Contact:Bret
ShapiroSr. Managing Partner, CORE
IR516-222-2560brets@coreir.com
Daxor (AMEX:DXR)
Historical Stock Chart
From Aug 2024 to Sep 2024
Daxor (AMEX:DXR)
Historical Stock Chart
From Sep 2023 to Sep 2024